JP2024520411A5 - - Google Patents

Info

Publication number
JP2024520411A5
JP2024520411A5 JP2023572721A JP2023572721A JP2024520411A5 JP 2024520411 A5 JP2024520411 A5 JP 2024520411A5 JP 2023572721 A JP2023572721 A JP 2023572721A JP 2023572721 A JP2023572721 A JP 2023572721A JP 2024520411 A5 JP2024520411 A5 JP 2024520411A5
Authority
JP
Japan
Prior art keywords
patient
approximately
viral vector
administered
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520411A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030716 external-priority patent/WO2022251208A1/en
Publication of JP2024520411A publication Critical patent/JP2024520411A/ja
Publication of JP2024520411A5 publication Critical patent/JP2024520411A5/ja
Pending legal-status Critical Current

Links

JP2023572721A 2021-05-24 2022-05-24 X連鎖性ミオチュブラーミオパチーの改善された治療のための組成物及び方法 Pending JP2024520411A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163192279P 2021-05-24 2021-05-24
US63/192,279 2021-05-24
US202163245611P 2021-09-17 2021-09-17
US63/245,611 2021-09-17
PCT/US2022/030716 WO2022251208A1 (en) 2021-05-24 2022-05-24 Compositions and methods for improved treatment of x-linked myotubular myopathy

Publications (2)

Publication Number Publication Date
JP2024520411A JP2024520411A (ja) 2024-05-24
JP2024520411A5 true JP2024520411A5 (cg-RX-API-DMAC7.html) 2025-05-30

Family

ID=84229086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572721A Pending JP2024520411A (ja) 2021-05-24 2022-05-24 X連鎖性ミオチュブラーミオパチーの改善された治療のための組成物及び方法

Country Status (13)

Country Link
US (1) US20240366785A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351725A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520411A (cg-RX-API-DMAC7.html)
KR (1) KR20240025536A (cg-RX-API-DMAC7.html)
AU (1) AU2022283262A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024509A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219834A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023018156A2 (cg-RX-API-DMAC7.html)
IL (1) IL308736A (cg-RX-API-DMAC7.html)
MX (1) MX2023013926A (cg-RX-API-DMAC7.html)
PH (1) PH12023553216A1 (cg-RX-API-DMAC7.html)
TW (1) TW202306589A (cg-RX-API-DMAC7.html)
WO (1) WO2022251208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125077A1 (es) * 2021-03-11 2023-06-07 Audentes Therapeutics Inc Composiciones y métodos para tratar la miopatía miotubular ligada a x

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6217938B2 (ja) * 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
US8957044B2 (en) * 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)

Similar Documents

Publication Publication Date Title
Pozsgai et al. Systemic AAV-mediated β-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice
US12357663B2 (en) Intrathecal delivery of recombinant adeno-associated virus encoding methyl-CpG binding protein 2
JP2023552443A (ja) ダノン病の治療
CN111542612B (zh) 用于治疗弗里德希氏共济失调的载体
JP2025514978A (ja) 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用
AU2022313258A1 (en) Auf1 combination therapies for treatment of muscle degenerative disease
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
US11952585B2 (en) Methods of treating phenylketonuria
RU2023134651A (ru) Композиции и способы улучшенного лечения х-сцепленной миотубулярной миопатии
JP2025523953A (ja) 肢帯型筋ジストロフィーのためのauf1遺伝子療法
Vogel et al. Effects of testosterone infusions upon EEGs of normal male adults
Leiba et al. Cushing’s disease coexisting with a single macronodule simulating adenoma of the adrenal cortex
JP2025505575A5 (cg-RX-API-DMAC7.html)
Liu et al. Combined Insulin-Glibenclamide Therapy of NIDDM Patients in Primary Health Care: A follow-up study of its compliance and efficacy and a review of the literature
Russell, D.,* Fritz, V.,** Mieny, CJ,** Mendelsohn, D.,* Joffe, BI*** & Seftel Treatment of familial hypercholesterolaemia by partial ileal bypass
Cuesta et al. Blau syndrome (familial granulomatous arthritis, iritis, and rash) in an African-American family
WO2021102435A1 (en) Materials and methods for treatment of disorders associated with the ighmbp2 gene
Khanna et al. P. 17.8 The co-formulation of pharmacological chaperone AT2220 with recombinant human acid alpha-glucosidase improves enzyme uptake and glycogen reduction in a mouse model of Pompe disease
JP2026012759A (ja) 筋ジストロフィーを治療するための方法および組成物
RU2024125625A (ru) Композиции и способы для оптимизированного лечения болезни помпе
SCHEMAN et al. PSEUDOHYPERTROPHIC MUSCULAR DYSTROPHY: AN EVALUATION OF RECENT STUDIES
Parsons Current Updates and Advances in Diagnosis and Treatment of Spinal Muscular Atrophy.
WO2022150469A1 (en) Methods and compositions for treating muscular dystrophy
IL294627A (en) Methods for treating phenalactonuria
TM et al. HYPERCALCAEMIA IN SARCOIDOSIS.